Table 1.

Audiometric and Imaging Data^a

Patient No./Age at Diagnosis	Organism	Days in ICU	Mechanical Ventilation?	Seizures	Other Significant Events	Type of Audiometry	Hearing Outcome		MRI Score		MRI Timing, Days After Diagnosis
							Right	Left	Right	Left
1/2.8 mo	P multocida	5	Y	N	8 Days of aminoglycoside therapy	Screening ABR	Normal	Normal	0	0	4
2/2.9 mo	P aeruginosa, blood	16	Y	Y	Craniotomy for subdural bleed; pseudomonas sepsis; 27 days of aminoglycoside therapy; Dex for 24 h around extubation, days 3–4b	Screening ABR	Normal	Normal	0	0	2
3/3.4 mo	S pneumoniae	6	N	Y	None	Screening ABR	Normal	Normal	0	0	2
4/3.4 mo	S pneumoniae	3	N	Y	None	ABR+OAEs	Normal	Normal	0	0	1
5/4.0 mo	Group B Streptococcus	No ICU		N	None	Screening ABR	Normal	Normal	0	0	15
6/4.0 mo	S pneumoniae	1	N	N	None	SF Audio + ES OAEs	Normal	Normal	0	0	4
7/4.3 mo	Group B Streptococcus (blood)	6	N	Y	None	Screening ABR	Normal	Normal	0	0	3
8/5.1 mo	S pneumoniae	5	N	Y	None	Screening ABR	Normal	Normal	0	0	3
9/16 mo	S pneumoniae	3	N	Y	None	ABR + OAEs	Normal	Normal	0	0	2
10/5.2 y	No growth	3	N	N	None	Audio + OAEs	Normal	Normal	0	0	0
11/6.5 y	N meningitidis	9	Y	Y	MCA stroke; craniotomy; ventriculostomy with ICP mgmt, 4 days; dopamine, 7 days	Audio	Normal	Normal	0	0	0
12/6.7 y	No growth	2	N	N	None	Audio	Normal	Normal	0	0	2
13/7.2 y	S pneumoniae, blood	No ICU	N	N	None	Audio	Normal	Normal	0	0	1
14/8.8 y	S pneumoniae	1	Y	Y	None	Audio	Normal	Normal	0	0	5
15/11 y	S pneumoniae	3	N	N	None	Audio	Normal	Normal	0	0	1
16/14 y	N meningitidis	4	N	Y	None	Audio	M-M HL	M-M HL	0	0	3
17/15 mo	S pneumoniae	5	N	N	None	SF Audio + ES OAEs	M-M HL	S-P HL	1	3	5
18/14 mo	S pneumoniae	2	N	N	Dopamine, 1 day	SF Audio + ES OAEs	S-P HL	S-P HL	2	2	8
19/13 y	S pneumoniae	3	Y	N	Sphenoid sinusitis; Gent, 2 days	Audio	M-M HL	S-P HL	2	3	7
20/5.5 mo	S pneumoniae	5	N	Y	Refractory seizures; multiple medications	SF Audio + ES OAEs	S-P HL	Normal	2	0	1
21/11 mo	S pneumoniae	17	Y	N	Bilateral MCA stroke; ventriculostomy and ICP mgmt for 12 days; 10 days of aminoglycoside therapy; spasticity; cognitive defect; single-dose MePred after strokeb	ABR + OAEs	S-P HL	S-P HL	2	2	5
22/16 mo	S pneumoniae	6	Y	Y	None	ABR	S-P HL	S-P HL	3	3	6
23/30 mo	S pneumoniae	6	Y	N	Multiple parietal infarcts; hypotonia; speech defect; leg paresis; Dex at outside hospital, days 1–2b	ABR	S-P HL	S-P HL	2–3	2–3	7

Abbreviations: ABR, auditory brainstem response; Audio, audiogram; Dex, dexamethasone; ES, ear-specific; Gent, gentamicin; ICP, intracranial pressure; ICU, intensive care unit; MCA, middle cerebral artery; MePred, methylprednisolone; mgmt, management; M-M HL, mild to moderate hearing loss; MRI, magnetic resonance imaging; N, no; N meningitidis, Neisseria meningitidis; OAE, otoacoustic emissions; P aeruginosa, Pseudomonas aeruginosa; P multocida, Pasteurella multocida; S pneumoniae, Streptococcus pneumoniae; SF, soundfield; S-P HL, severe to profound hearing loss; Tobra, tobramycin; Y, yes.

^aPatients are listed in order of hearing outcome. All ABRs were ear specific.

^bPatients who received corticosteroids.